Japan Tissue Engineering Co (TSE:7774) ROCE %: 1.06% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7774 Japan Tissue Engineering Co Ltd TSE:7774
58 GF Score
Price 円860.00
GF Value 円505.19
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Japan Tissue Engineering Co ROCE %?

Japan Tissue Engineering Co TSE:7774 -0.23% 58 ROCE % is 1.06% as of Mar. 2026. GuruFocus rates TSE:7774 with a GF Score™ of 58/100 and a GF Value™ of 円505.19 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Japan Tissue Engineering Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.06%.

Japan Tissue Engineering Co  (TSE:7774) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Japan Tissue Engineering Co ROCE % Related Terms

Japan Tissue Engineering Co ROCE % Historical Data

* Premium members only.

The historical data trend for Japan Tissue Engineering Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Japan Tissue Engineering Co ROCE % Chart

Japan Tissue Engineering Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.17 -11.49 2.39 -3.97 -9.99

Japan Tissue Engineering Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.02 -9.49 -13.88 1.06 4.60
TSE:7774
58GF Score
Japan Tissue Engineering Co Ltd TSE:7774
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Japan Tissue Engineering Co ROCE % Calculation

Japan Tissue Engineering Co's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-549.44/( ( (6512.99 - 637.229) + (5682.993 - 560.509) )/ 2 )
=-549.44/( (5875.761+5122.484)/ 2 )
=-549.44/5499.1225
=-9.99 %

Japan Tissue Engineering Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=55.132/( ( (5890.709 - 589.671) + (5682.993 - 560.509) )/ 2 )
=55.132/( ( 5301.038 + 5122.484 )/ 2 )
=55.132/5211.761
=1.06 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 1.06% mean?
Japan Tissue Engineering Co (TSE:7774) has a ROCE % of 1.06% as of Mar. 2026.
Is Japan Tissue Engineering Co's ROCE % too high?
Japan Tissue Engineering Co's current ROCE % is 1.06%. Overall, Japan Tissue Engineering Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's ROCE % compare to VRTX and REGN?
Japan Tissue Engineering Co's ROCE % of 1.06% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Japan Tissue Engineering Co's current ROCE % is 1.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Significantly Overvalued. The stock's GF Value™ is 円505.19, compared to a current price of 円860.00 — trading 70.2% above its estimated fair value. The current ROCE % is 1.06%. Japan Tissue Engineering Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current ROCE % is 1.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?

Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued. The current stock price of 円860.00 is trading 70.2% above its estimated GF Value™ of 円505.19. GuruFocus considers Japan Tissue Engineering Co to be Significantly Overvalued.

Key valuation signals for TSE:7774:

  • ROCE %: 1.06%
  • GF Value™: 円505.19 vs. price of 円860.00 (70.2% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Japan Tissue Engineering Co Business Description

Address 6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
58GF Score

Get the complete analysis for TSE:7774

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円860.00
Price
円505.19
GF Value